Dermatan sulfate from Styela plicata

new natural compound candidate for wound healing treatment

Abstract

Skin wound healing is a biological complex phenomenon that presents in four classical phases: homeostasis, inflammation, proliferation and remodeling. Fibroblasts are present from the end of the inflammatory phase to complete tissue epithelization. The cellular mechanisms that drive this process have not yet been fully elucidated. Dermatan sulfate is the main skin glycosaminoglycan acting on fibroblast proliferation and modulation of fibrogenic activity. Dermatan s u l f a t e isol a t ed fro m m a ri n e invertebrates, such as Styela plicata, showed showed that they lack the effect of platelet aggregation and showed no bleeding effect in in vivo tests. Due to this background, the main objective of this study was to investigate the effects of dermatan sulfate from S. plicata on cell viability and migration of dermal fibroblasts in vitro. Mouse dermal fibroblasts were cultivated and used for viability and migration assays, in vitro, against different compound concentrations, at different times of incubation. The results showed that the compounds did not alter cell viability until 72 h of incubation and the cells migrated to the center of the wound after 24 h of incubation with 50 μg / mL. This study demonstrated that the dermatan sulfate extracted from S. plicata was effective in promoting and accelerating the wound closure process in dermal fibroblasts, in vitro. This agent has proved to be a potential target in the development of novel natural therapeutic agents for the treatment of wounds, especially those of difficult resolution. Keywords: Wound healing. Fibroblasts. Dermatan sulfate. Styela plicata.